Paediatric Section, Department of Surgery, Dentistry, Paediatrics, and Gynaecology, University of Verona, Verona, Italy.
Pediatr Allergy Immunol. 2020 Nov;31 Suppl 26:14-16. doi: 10.1111/pai.13374.
Interleukin (IL)-5 is a potent mediator of the inflammatory cascade in the allergic response. Its predominant role in atopic reactions makes this cytokine an ideal target for blocking the eosinophilic inflammatory hyper-responsiveness to allergens. The management of allergic diseases in childhood-such as severe asthma, atopic dermatitis, and eosinophilic esophagitis-is a challenge. In particular, there are concerns regarding the use of high-dose corticosteroids. Over the last few years, biologics targeting IL-5 or IL-5 receptor-that are mepolizumab, reslizumab, and benralizumab-represent a new, promising, and more personalized therapeutic option.
白细胞介素 (IL)-5 是过敏反应中炎症级联的一种有效介质。它在特应性反应中的主要作用使这种细胞因子成为阻断过敏原引起的嗜酸性炎症高反应性的理想靶点。儿童期过敏疾病的管理——如严重哮喘、特应性皮炎和嗜酸性食管炎——是一个挑战。特别是，人们对使用高剂量皮质类固醇存在担忧。在过去几年中，针对白细胞介素-5 或白细胞介素-5 受体的生物制剂——美泊利珠单抗、瑞利珠单抗和贝那利珠单抗——代表了一种新的、有前途的、更个性化的治疗选择。
